Promising Gene Therapy for Huntington’s Disease
A new gene therapy has shown potential in slowing the advancement of Huntington’s disease, bringing a glimmer of hope for those with this currently incurable condition that progressively harms brain cells.
Uniqure, the company behind the therapy, shared some intriguing results from its Phase I/II study this week. They reported that high doses of the AMT-130 therapy managed to slow disease progression by a remarkable 75% after three years of treatment.
Dr. Walid Abi Shab, Uniqure’s chief medical officer, highlighted the importance of these findings, suggesting that AMT-130 could “transform the treatment landscape for Huntington’s disease.” He also emphasized the value of a one-time, precisely administered gene therapy as a potential breakthrough for neurological disorders.
Currently, around 42,000 individuals in the U.S. are living with Huntington’s, while another 200,000 are at risk of inheriting it, according to the Huntington’s Disease Association in America. This genetic disorder stems from a mutation on chromosome 4, specifically affecting the Huntingtin (HTT) gene.
The problematic genetic mutations lead to an abnormal form of the huntingtin protein, which becomes excessively long and misfolded, creating toxic aggregates that compromise brain cell functionality.
Typically, symptoms such as involuntary movements and cognitive decline emerge in a person’s 30s to 40s. As the disease progresses, patients often face significant challenges like dementia, speech difficulties, and mobility issues, necessitating round-the-clock care.
In the clinical trial conducted by Uniqure, 12 out of 29 participants were monitored over three years following the administration of high-dose AMT-130 therapy. Their disease progression was then compared with a control group of untreated individuals.
This gene therapy employs a harmless virus to introduce permanent DNA into brain cells, effectively reducing the production of the harmful huntingtin protein. Remarkably, a single treatment dose is expected to provide long-lasting results.
Uniqure reported that the treatment was “generally well tolerated,” with the main adverse effects associated with the method of administration, all of which were resolved.
Although the findings have yet to be reviewed by peers, they are anticipated to be presented at the upcoming HD Clinical Research Conference in Nashville next month.
The company aims to submit its data for FDA approval in the first quarter of 2026, with hopes to make the treatment available in the U.S. sometime next year.
Currently, while there is no cure for Huntington’s disease, treatment options exist to alleviate several symptoms through medications, physical therapy, speech and occupational therapy, and nutritional support.
“Of course, we’ll need to see the comprehensive results from peer review, but this is a promising development that could provide genuine hope to families affected by the disease,” remarked a director at the UK Institute of Dementia, who wasn’t part of the study. “The logical next step would be to progress to larger, more advanced trials for this drug.”
